Montag & Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21M Sell
50,191
-88
-0.2% -$2.3K 0.05% 228
2026
Q1
$1.41M Sell
50,279
-2,402
-5% -$63.9K 0.07% 207
2025
Q4
$1.31M Sell
52,681
-470
-0.9% -$11.9K 0.06% 205
2025
Q3
$1.35M Sell
53,151
-9,159
-15% -$226K 0.06% 204
2025
Q2
$1.51M Sell
62,310
-4,884
-7% -$114K 0.07% 193
2025
Q1
$1.7M Sell
67,194
-8,468
-11% -$222K 0.09% 181
2024
Q4
$2.01M Sell
75,662
-4,810
-6% -$130K 0.1% 169
2024
Q3
$2.33M Sell
80,472
-679
-0.8% -$19.8K 0.11% 167
2024
Q2
$2.27M Sell
81,151
-7,641
-9% -$210K 0.11% 151
2024
Q1
$2.46M Sell
88,792
-23,977
-21% -$665K 0.12% 154
2023
Q4
$3.25M Sell
112,769
-2,430
-2% -$73.5K 0.18% 120
2023
Q3
$3.82M Sell
115,199
-8,695
-7% -$307K 0.24% 92
2023
Q2
$4.54M Buy
123,894
+726
+0.6% +$28.3K 0.28% 84
2023
Q1
$5.03M Buy
123,168
+1,903
+2% +$82.2K 0.33% 78
2022
Q4
$6.21M Sell
121,265
-2,345
-2% -$112K 0.42% 64
2022
Q3
$5.41M Buy
123,610
+1,296
+1% +$63K 0.37% 73
2022
Q2
$6.41M Sell
122,314
-1,620
-1% -$82.6K 0.41% 62
2022
Q1
$6.42M Sell
123,934
-614
-0.5% -$31.9K 0.34% 80
2021
Q4
$7.36M Sell
124,548
-6,137
-5% -$304K 0.36% 79
2021
Q3
$5.62M Sell
130,685
-6,463
-5% -$286K 0.3% 91
2021
Q2
$5.37M Buy
137,148
+187
+0.1% +$7.27K 0.29% 95
2021
Q1
$4.96M Sell
136,961
-7,428
-5% -$264K 0.28% 102
2020
Q4
$5.32M Sell
144,389
-3,837
-3% -$141K 0.33% 81
2020
Q3
$5.16M Sell
148,226
-2,187
-1% -$76.7K 0.42% 69
2020
Q2
$4.67M Sell
150,413
-485
-0.3% -$16.5K 0.41% 71
2020
Q1
$4.67M Sell
150,898
-7,504
-5% -$256K 0.47% 62
2019
Q4
$5.89M Sell
158,402
-5,873
-4% -$209K 0.47% 58
2019
Q3
$5.6M Sell
164,275
-38,010
-19% -$1.38M 0.49% 54
2019
Q2
$8.31M Sell
202,285
-7,641
-4% -$303K 0.74% 38
2019
Q1
$8.46M Sell
209,926
-12,657
-6% -$507K 0.78% 33
2018
Q4
$9.22M Sell
222,583
-803
-0.4% -$33.3K 0.99% 25
2018
Q3
$9.34M Buy
223,386
+20,035
+10% +$771K 0.82% 31
2018
Q2
$7M Buy
203,351
+3,439
+2% +$118K 0.72% 35
2018
Q1
$6.73M Buy
199,912
+2,322
+1% +$79.8K 0.69% 38
2017
Q4
$6.79M Sell
197,590
-3,572
-2% -$122K 0.66% 41
2017
Q3
$6.81M Sell
201,162
-1,878
-0.9% -$60.4K 0.73% 35
2017
Q2
$6.47M Buy
203,040
+5,953
+3% +$188K 0.73% 40
2017
Q1
$6.4M Sell
197,087
-4,285
-2% -$135K 0.72% 42
2016
Q4
$6.21M Buy
201,372
+2,431
+1% +$74.2K 0.73% 40
2016
Q3
$6.39M Buy
198,941
+1,848
+0.9% +$61.8K 0.81% 33
2016
Q2
$6.58M Buy
197,093
+316
+0.2% +$10.1K 0.87% 32
2016
Q1
$5.53M Sell
196,777
-6,588
-3% -$188K 0.78% 34
2015
Q4
$6.23M Buy
203,365
+1,850
+0.9% +$58.2K 0.91% 26
2015
Q3
$6M Buy
201,515
+10,013
+5% +$321K 0.94% 29
2015
Q2
$6.09M Sell
191,502
-3,408
-2% -$111K 0.89% 34
2015
Q1
$6.43M Sell
194,910
-3,124
-2% -$99.3K 0.93% 27
2014
Q4
$5.85M Buy
198,034
+4,321
+2% +$124K 0.88% 34
2014
Q3
$5.43M Sell
193,713
-2,161
-1% -$60.6K 0.9% 31
2014
Q2
$5.52M Sell
195,874
-68,630
-26% -$1.96M 0.9% 32
2014
Q1
$8.06M Sell
264,504
-15,879
-6% -$473K 1.36% 14
2013
Q4
$8.15M Buy
280,383
+4,601
+2% +$134K 1.4% 15
2013
Q3
$7.52M Buy
275,782
+6,958
+3% +$189K 1.4% 14
2013
Q2
$7.14M Buy
+268,824
New +$7.43M 1.46% 9

Other funds holding PFE

Montag & Associates's PFE Position: Q2 2026 in Review

Montag & Associates reduced its Pfizer (PFE) stake by 0.18% in Q2 2026, selling an estimated $2.3K and leaving 50,191 shares worth $1.21M. The position accounts for 0.05% of the portfolio, ranked #228.

Montag & Associates first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.34M in Q3 2018. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Montag & Associates held 50,191 shares of Pfizer worth $1.21M as of Q2 2026.
  • Montag & Associates sold 88 Pfizer shares in Q2 2026, an estimated $2.3K.
  • Pfizer made up 0.05% of Montag & Associates's portfolio in Q2 2026, its #228 holding.
  • Montag & Associates first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Montag & Associates's Pfizer position peaked at $9.34M in Q3 2018.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.